FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali
Double Blind Randomized, Controlled Phase 1 Dose Escalation Trial to Evaluate the Safety and Immunogenicity of the WRAIR AMA1 Malaria Antigen (FMP2.1) Adjuvanted in GSK's AS02A Versus Rabies Vaccine in Malaria-experienced Adults in Bandiagara, Mali
Sponsor: GlaxoSmithKline
This PHASE1 trial investigates Malaria and Plasmodium Falciparum Malaria and is currently completed. GlaxoSmithKline leads this study, which shows 12 recorded versions since 2004 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1
-
Mar 2022 — Dec 2022 [monthly]
Completed PHASE1
▶ Show 7 earlier versions
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE1
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Aug 2019 — Sep 2019 [monthly]
Completed PHASE1
-
Jun 2018 — Aug 2019 [monthly]
Completed PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Feb 2017 — Aug 2017 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Nov 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- National Institute of Allergy and Infectious Diseases (NIAID)
- U.S. Army Medical Research and Development Command
- University of Maryland
- Walter Reed Army Institute of Research (WRAIR)
For direct contact, visit the study record on ClinicalTrials.gov .